FindTrial
Sign In

Exploring the molecular mechanism of PIAS1 regulating ferroptosis by activating the TAL1/SLC7A11 axis and affecting the occurrence and development of non-small cell lung cancer based on SUMOylation modification

Exploring the molecular mechanism of PIAS1 regulating ferroptosis by activating the TAL1/SLC7A11 axis and affecting the occurrence and development of non-small cell lung cancer based on SUMOylation modification

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117268
Enrollment
Unknown
Registered
2026-01-21
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Group of non-small cell lung cancer:None

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age limit: 25-75 years old, participants can decide the details of the experiment on their own; Both genders are acceptable; 2.ECOG<=2;NRS2002<=1; 3.Newly diagnosed non-small cell lung cancer patients without a history of radiotherapy or chemotherapy;

Exclusion criteria

Exclusion criteria: 1.Hematological diseases such as hemorrhagic purpura or coagulation dysfunction, or inability to collect blood samples or undergo surgical treatment due to various reasons; 2.Have any history of malignant tumors;

Design outcomes

Primary

MeasureTime frame
expression of PIAS1;expression of TAL1;expression of SLC7A11;expression of Fe2+;—

Countries

China

Contacts

Public ContactLiji Wang

Ningbo Medical Centre Lihuili Hospital

dlwangljnb@163.com+86 574 5583 6258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026